NEUROCRINE BIOSCIENCES INC Amortization of Debt Discount (Premium)
NEUROCRINE BIOSCIENCES INC (NBIX) reported Amortization of Debt Discount (Premium) of $126.60 million for the 12-month period ending 2024-12-31, per its 10-K filed 2026-02-11.
Financial Statements › Cash Flow › Operating Activities
us-gaap:AmortizationOfDebtDiscountPremium · last filed 2026-02-11
- NEUROCRINE BIOSCIENCES INC amortization of debt discount (premium) for the quarter ending 2024-12-31 was $0.00.
- NEUROCRINE BIOSCIENCES INC amortization of debt discount (premium) for the quarter ending 2024-09-30 was $0.00.
- NEUROCRINE BIOSCIENCES INC amortization of debt discount (premium) for the quarter ending 2024-06-30 was $47.50M.
- NEUROCRINE BIOSCIENCES INC amortization of debt discount (premium) for the quarter ending 2024-03-31 was $79.10M.
- NEUROCRINE BIOSCIENCES INC amortization of debt discount (premium) for fiscal 2024 was $126.60M.
- NEUROCRINE BIOSCIENCES INC amortization of debt discount (premium) for fiscal 2023 was $0.00.
- NEUROCRINE BIOSCIENCES INC amortization of debt discount (premium) for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
- NEUROCRINE BIOSCIENCES INC amortization of debt discount (premium) for fiscal 2021 was $16.20M, a 19.00% decline from fiscal 2020.
| Period end | Amortization of Debt Discount (Premium) 3 month | Amortization of Debt Discount (Premium) 3 month as first filed | Amortization of Debt Discount (Premium) 6 month | Amortization of Debt Discount (Premium) 6 month as first filed | Amortization of Debt Discount (Premium) 9 month | Amortization of Debt Discount (Premium) 9 month as first filed | Amortization of Debt Discount (Premium) 12 month | Amortization of Debt Discount (Premium) 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $0.00 derived: sum of 2 quarters · filed 2026-02-11 | $47.50M derived: sum of 3 quarters · filed 2026-02-11 | $126.60M 10-K · filed 2026-02-11 | ||||
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-28 | $47.50M derived: sum of 2 quarters · filed 2025-10-28 | $126.60M 10-Q · filed 2025-10-28 | |||||
| 2024-06-30 | $47.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-30 | $126.60M 10-Q · filed 2025-07-30 | ||||||
| 2024-03-31 | $79.10M 10-Q · filed 2025-05-05 | |||||||
| 2023-12-31 | $0.00 10-K · filed 2024-02-09 | |||||||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-09 | $0.00 derived: sum of 2 quarters · filed 2024-02-09 | $0.00 derived: sum of 3 quarters · filed 2024-02-09 | $0.00 10-K · filed 2024-02-09 | ||||
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-01 | $0.00 derived: sum of 2 quarters · filed 2022-11-01 | $0.00 10-Q · filed 2022-11-01 | $4.10M derived: sum of 4 quarters · filed 2024-02-09 | ||||
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $0.00 10-Q · filed 2022-08-04 | $4.10M derived: sum of 3 quarters · filed 2024-02-09 | $8.30M derived: sum of 4 quarters · filed 2024-02-09 | ||||
| 2022-03-31 | $0.00 10-Q · filed 2022-05-04 | $4.10M derived: sum of 2 quarters · filed 2024-02-09 | $8.30M derived: sum of 3 quarters · filed 2024-02-09 | $12.30M derived: sum of 4 quarters · filed 2024-02-09 | ||||
| 2021-12-31 | $4.10M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-09 | $8.30M derived: sum of 2 quarters · filed 2024-02-09 | $12.30M derived: sum of 3 quarters · filed 2024-02-09 | $16.20M 10-K · filed 2024-02-09 | ||||
| 2021-09-30 | $4.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-01 | $8.20M derived: sum of 2 quarters · filed 2022-11-01 | $12.10M 10-Q · filed 2022-11-01 | $16.90M derived: sum of 4 quarters · filed 2023-02-09 | ||||
| 2021-06-30 | $4.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $7.90M 10-Q · filed 2022-08-04 | $12.70M derived: sum of 3 quarters · filed 2023-02-09 | $17.90M derived: sum of 4 quarters · filed 2023-02-09 | ||||
| 2021-03-31 | $3.90M 10-Q · filed 2022-05-04 | $8.70M derived: sum of 2 quarters · filed 2023-02-09 | $13.90M derived: sum of 3 quarters · filed 2023-02-09 | $18.90M derived: sum of 4 quarters · filed 2023-02-09 | ||||
| 2020-12-31 | $4.80M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-09 | $10.00M derived: sum of 2 quarters · filed 2023-02-09 | $15.00M derived: sum of 3 quarters · filed 2023-02-09 | $20.00M 10-K · filed 2023-02-09 | ||||
| 2020-09-30 | $5.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-01 | $10.20M derived: sum of 2 quarters · filed 2021-11-01 | $15.20M 10-Q · filed 2021-11-01 | $20.00M derived: sum of 4 quarters · filed 2022-02-11 | ||||
| 2020-06-30 | $5.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-03 | $10.00M 10-Q · filed 2021-08-03 | $14.80M derived: sum of 3 quarters · filed 2022-02-11 | $19.60M derived: sum of 4 quarters · filed 2022-02-11 | ||||
| 2020-03-31 | $5.00M 10-Q · filed 2021-05-05 | $9.80M derived: sum of 2 quarters · filed 2022-02-11 | $14.60M derived: sum of 3 quarters · filed 2022-02-11 | $19.30M derived: sum of 4 quarters · filed 2022-02-11 | ||||
| 2019-12-31 | $4.80M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-11 | $9.60M derived: sum of 2 quarters · filed 2022-02-11 | $14.30M derived: sum of 3 quarters · filed 2022-02-11 | $18.90M 10-K · filed 2022-02-11 | $18.92M 10-K · filed 2020-02-07 | |||
| 2019-09-30 | $4.80M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | $9.50M derived: sum of 2 quarters · filed 2020-11-09 | $14.10M 10-Q · filed 2020-11-09 | $14.06M 10-Q · filed 2019-11-04 | $18.66M derived: sum of 4 quarters · filed 2021-02-05 | |||
| 2019-06-30 | $4.70M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-03 | $9.30M 10-Q · filed 2020-08-03 | $9.28M 10-Q · filed 2019-07-29 | $13.86M derived: sum of 3 quarters · filed 2021-02-05 | $18.29M derived: sum of 4 quarters · filed 2021-02-05 | |||
| 2019-03-31 | $4.60M 10-Q · filed 2020-05-06 | $4.60M 10-Q · filed 2019-04-29 | $9.16M derived: sum of 2 quarters · filed 2021-02-05 | $13.59M derived: sum of 3 quarters · filed 2021-02-05 | $17.93M derived: sum of 4 quarters · filed 2021-02-05 | |||
| 2018-12-31 | $4.56M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-05 | $8.99M derived: sum of 2 quarters · filed 2021-02-05 | $13.34M derived: sum of 3 quarters · filed 2021-02-05 | $17.60M 10-K · filed 2021-02-05 | $17.55M 10-K · filed 2019-02-08 | |||
| 2018-09-30 | $4.43M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-04 | $8.78M derived: sum of 2 quarters · filed 2019-11-04 | $13.04M 10-Q · filed 2019-11-04 | $17.22M derived: sum of 4 quarters · filed 2020-02-07 | ||||
| 2018-06-30 | $4.35M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-07-29 | $8.61M 10-Q · filed 2019-07-29 | $12.79M derived: sum of 3 quarters · filed 2020-02-07 | $16.90M derived: sum of 4 quarters · filed 2020-02-07 | ||||
| 2018-03-31 | $4.26M 10-Q · filed 2019-04-29 | $8.45M derived: sum of 2 quarters · filed 2020-02-07 | $12.55M derived: sum of 3 quarters · filed 2020-02-07 | $15.20M derived: sum of 4 quarters · filed 2020-02-07 | ||||
| 2017-12-31 | $4.18M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-07 | $8.29M derived: sum of 2 quarters · filed 2020-02-07 | $10.94M derived: sum of 3 quarters · filed 2020-02-07 | $10.94M 10-K · filed 2020-02-07 | ||||
| 2017-09-30 | $4.10M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-05 | $6.75M derived: sum of 2 quarters · filed 2018-11-05 | $6.75M 10-Q · filed 2018-11-05 | $6.75M derived: sum of 4 quarters · filed 2019-02-08 | ||||
| 2017-06-30 | $2.65M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-07-31 | $2.65M 10-Q · filed 2018-07-31 | $2.65M derived: sum of 3 quarters · filed 2019-02-08 | $2.65M derived: sum of 4 quarters · filed 2019-02-08 | ||||
| 2017-03-31 | $0.00 10-Q · filed 2018-04-30 | $0.00 derived: sum of 2 quarters · filed 2019-02-08 | $0.00 derived: sum of 3 quarters · filed 2019-02-08 | |||||
| 2016-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-08 | $0.00 derived: sum of 2 quarters · filed 2019-02-08 | $0.00 10-K · filed 2019-02-08 | |||||
| 2016-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-01 | $0.00 10-Q · filed 2017-11-01 | ||||||
| 2016-06-30 | $0.00 10-Q · filed 2017-08-03 | |||||||
| 2015-12-31 | $0.00 10-K · filed 2018-02-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |